US FDA cancels panel review of Lux uveitis drug
This article was originally published in Scrip
Executive Summary
The US FDA has cancelled a meeting of its dermatology and ophthalmology drugs advisory committee that had been scheduled for 28 June to discuss data on Lux Biosciences' immunosuppressant Luveniq (voclosporin, LX211) for treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye.